Key Takeaway: The article indicates a potential positive development for Alzheimer's disease patients, but it primarily consists of a disclaimer regarding third-party websites. There is no specific information provided about the advancements or research related to Alzheimer's treatment.
Price reaction · baseline $1.73 (2023-07-20 close) · hit after-hours · clean, no other CGTX news in the window
day 0 close
+9.2%
day 1 · peak
+9.8%
day 3
+1.2%
Market Sentiment Analysis
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+35%
120-day peak, hindsight
Typical move
8.3%
average across 6 past catalysts
Cash runway
~33 mo
Minimal dilution risk
Lead asset
Oxytocin
Phase 2 · Oxidative Stress
Full Press Release Details
You are now leaving the Cognition Therapeutics website
Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.